June 28, 2018 Article in European Biotechnology Magazine Summer 2018 „Combining established and novel technologies”
For its Summer Edition 2018, European Biotechnology spoke with Federico Pollano about the impact Leukocare's SPS® technology will have on the market and how Rentschler Biopharma combines tried-and-tested technologies with new innovations to lead the CDMO market.
Last year, Rentschler Biopharma partnered with Leukocare to complement their capabilities in formulation development. Particularly in the US, the company has won new customers, who want to replace the standard formulation of their compound with features that extend the unique selling proposition of the molecule. This is only one example of how Rentschler Biopharma complements their portfolio as a full-service CDMO with solutions that give their customers a competitive edge.
To meet the requirements of the future, Rentschler Biopharma is currently working on the implementation of its "Strategy 2025". The company wants to reinforce their position as a technology leader, thereby expanding into regions where Rentschler Biopharma has not been very active in the past, including Asia. Furthermore, Rentschler Biopharma will continue using their tried-and-tested technologies but also broaden their already substantial knowledge of molecular entities, e.g. bispecific antibodies, as well as new therapeutic modalities.
Download the full interview here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication